Abstract
While carcinogenesis is known to induce various alterations in epithelial cell polarity, little information is available about the fate of plasma membrane polarity during the neoplastic process. Using three monoclonal antibody-defined antigens as markers of the three plasma membrane domains of rat hepatocytes, the sinusoidal, the lateral, and the canalicular, we demonstrated by immunohistochemical techniques that changes in hepatocyte plasma membrane polarity occur at every stage of 3′-methyldimethylaminoazobenzene-induced hepatocarcinogenesis. At the preneoplastic stage, the division of hepatocyte plasma membrane into three distinct domains was retained despite rearrangements in hepatocytic architecture, characterized by the disorganization of hepatocytic plates and the formation of pseudoacinar structures. The most striking change was the distribution of the canalicular-associated antigen over the entire plasma membrane in disorganized plates. At the neoplastic stage, changes in plasma membrane polarity depended on the degree of morphological differentiation of neoplastic cells. Poorly differentiated cells inconstantly expressed the monoclonal antibody-defined antigens and showed no evidence of plasma membrane polarization. Differentiated cells constantly expressed the three antigens, and their plasma membrane was divided into antigenically distinct domains. The changes in hepatocyte plasma membrane polarity demonstrated in situ during 3′-methyldimethylaminoazobenzene hepatocarcinogenesis may therefore be compared with situations known to occur in vitro, in cultured epithelial cells presenting varying degrees of polarization. Our observations suggest that these alterations are of relevance to the in vivo biology of cancer.
Footnotes
-
↵1 This work was supported in part by grants from the Fondation pour la Recherche Médicale and from the Conseil Scientifique, Faculté Xavier Bichat, Université Paris VII.
-
↵2 To whom requests for reprints should be addressed.
- Received December 30, 1987.
- Revision received August 2, 1988.
- Accepted August 18, 1988.
- ©1988 American Association for Cancer Research.